COMBI-i (NCT02967692)[151] is a three-part randomized phase III trial testing investigational anti-PD-1 antibody spartalizumab in combination with dabrafenib plus trametinib (Sparta-DabTram) vs. placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600 advanced melanoma. The gene discussed is BRAF; the disease is melanoma.